Home
Pharma News
CDM
Clinical Research
Medical Writing
Regulatory Affairs
More
Clinical coding (Medical)
Clinical Research Associate
Centralized Monitoring
HEOR (Health Economics and Outcome Research)
Pharmacovigilanc​e
Scientific Writing
Other
About us
Search
CLINSQUARE: CLINICAL RESEARCH COURSES
Friday, April 26, 2024
Home
Pharma News
CDM
Clinical Research
Medical Writing
Regulatory Affairs
More
Clinical coding (Medical)
Clinical Research Associate
Centralized Monitoring
HEOR (Health Economics and Outcome Research)
Pharmacovigilanc​e
Scientific Writing
Other
About us
Facebook
Twitter
CLINSQUARE: Clinical Rsearch Courses by LIFEPRONOW
Home
Pharma News
CDM
Clinical Research
Medical Writing
Regulatory Affairs
More
Clinical coding (Medical)
Clinical Research Associate
Centralized Monitoring
HEOR (Health Economics and Outcome Research)
Pharmacovigilanc​e
Scientific Writing
Other
About us
Search
Home
Latest Pharma-News
Latest Pharma-News
Latest Pharma-News
FDA Takes Steps to Ensure Safety of Cinnamon Products Sold in the US
admin
-
March 8, 2024
Latest Pharma-News
FDA Clears First Over-the-Counter Continuous Glucose Monitor
admin
-
March 8, 2024
Latest Pharma-News
FDA, Industry Actions End Sales of PFAS Used in US Food Packaging
admin
-
March 1, 2024
Latest Pharma-News
Regulatory Applications Accepted in the U.S. and Japan for BMS Breyanzi in Relapsed or Refractory FL and Relapsed or Refractory MCL
admin
-
February 3, 2024
Latest Pharma-News
BlueRock Therapeutics exercises exclusive option to license iPSC cell therapy candidate OpCT-001 for Primary Photoreceptor Diseases
admin
-
February 1, 2024
Latest Pharma-News
FDA OKs to Navigen for its IND Application to Initiate First-in-Human Studies for CPT31, a Novel, D-peptide HIV Entry Inhibitor
admin
-
December 11, 2019
0
Latest Pharma-News
Sesen Bio Initiates Rolling Submission of BLA for Vicinium to FDA for the treatment of BCG-unresponsive non-muscle invasive bladder cancer
admin
-
December 11, 2019
0
Latest Pharma-News
First and only ingestible event marker (the ID-Cap® System)approved by U.S. FDA
admin
-
December 11, 2019
0
Latest Pharma-News
Moberg Pharma meets primary endpoint for MOB-015 (topical terbinafine) in a phase 3 study for the treatment of Onychomycosis
admin
-
December 10, 2019
0
Latest Pharma-News
U.S. FDA approved Fast Track designation for Equillium’s itolizumab (EQUALISE Phase 1b study )for the treatment of lupus nephritis
admin
-
December 10, 2019
0
Latest Pharma-News
Only treatment approved in the US for relapsed or refractory hairy cell leukemia Approved by FDA at ASH 2019
admin
-
December 9, 2019
0
Latest Pharma-News
Amgen’s AVSOLA™ received FDA approval for AVSOLA™ (infliximab-axxq), For The Same Indications As Remicade® (infliximab)for the treatment of Rheumatoid Arthritis, Crohn’s Disease, Ulcerative Colitis,...
admin
-
December 9, 2019
0
Latest Pharma-News
ViiV Healthcare submits New Drug Application to the US FDA for fostemsavir, an investigational, first-in-class attachment inhibitor for the treatment of HIV in adults
admin
-
December 9, 2019
0
Latest Pharma-News
FDA authorizes marketing of diagnostic test cobas vivoDx that uses novel technology to detect Methicillin-resistant Staphylococcus aureus (MRSA) bacteria
admin
-
December 9, 2019
0
Latest Pharma-News
First investigational drug therapy for liver disease non alcoholic steatohepatitis (NASH) awaiting FDA approval
admin
-
December 9, 2019
0
Latest Pharma-News
Data fron XOSPATA® in FLT3 Mutation-Positive Relapsed/Refractory Acute Myeloid Leukemia at the 2019 American Society of Hematology Annual Meeting
admin
-
December 9, 2019
0
Latest Pharma-News
First generics of Gilenya approved by FDA for the treatment of relapsing forms of multiple sclerosis (MS) in adult patients
admin
-
December 6, 2019
0
1
...
137
138
139
...
144
Page 138 of 144
- Advertisment -
Most Read
FDA Takes Steps to Ensure Safety of Cinnamon Products Sold in the US
March 8, 2024
FDA Clears First Over-the-Counter Continuous Glucose Monitor
March 8, 2024
FDA, Industry Actions End Sales of PFAS Used in US Food Packaging
March 1, 2024
Regulatory Applications Accepted in the U.S. and Japan for BMS Breyanzi in Relapsed or Refractory FL and Relapsed or Refractory MCL
February 3, 2024